Remoroza, Trixie F.
HRN: 21-47-73 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
06/22/2022
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
06/22/2022
06/29/2022
IV
90
Q24
Pcap C
Waiting Final Action
Indication: Empiric Type of Infection: Pneumonia Compliance to guidelines: Guideline Not Available
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes